Conference Reports for NATAP

Back

16th European AIDS Conference October 25-27 2017 Milan, Italy     Meta-analysis of safety for DTG versus other ARVs in randomized trials: Analysis of cardiovascular, CNS and IRIS endpoints - (01/04/18)   HCV Reinfection Intervention in HCV/HIV MSM - Swiss Cohort - (01/04/18)   Characterization of the Aging Population Living with HIV in Portugal: a multicentre, observational study to evaluate comorbidities in patients above 50 years of age - AGING POSITIVE - (12/14/17)   BESIDE - FIRST NATIONWIDE ANALYSIS OF RECREATIONAL/ILLICIT DRUG USE IN HIV-INFECTED INDIVIDUALS IN GERMANY SHOWS HIGH PREVALENCE OF SUBSTANCE ABUSE WITH A POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)   BESIDE - HIGH PREVALENCE OF COMORBIDITIES AND CONCOMITANT MEDICATION IN HIV-INFECTED PATIENTS IN GERMANY CARRIES A HIGH POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)   Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location - (12/13/17)   Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Results From the SWORD-1 and SWORD-2 Studies - (12/12/17)   How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)   Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)   Aging in Portugal: The number of PLHIV aged 50+ will double in the next 20 years, representing 80% of the estimated overall prevalence in 2037. The proportion over 70 will increase 4.3 times going from 6% to 26%. - (12/06/17)   SAFETY ANALYSIS OF GERMAN REAL-LIFE COHORT WIP SHOWS LOW RATES OF NEUROPSYCHIATRIC EVENTS LEADING TO DISCONTINUATION OF RALTEGRAVIR THERAPY - (12/06/17)   Dynamics of viral rebound and development of resistance associated mutations in the DOlutegravir maintenance MONOtherapy (DOMONO) study. - (12/06/17)   Changes outside integrase in a patient failing on dolutegravir maintenance monotherapy points to a new resistance mechanism - (11/16/17)   Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)   Weight Gain & Affects of Different cART Regimens: PIs, NNRTIs, Integrase - Mark Mascolini (11/08/17)   Higher Pre-ART Viral Load Predicts Death in 12,000-Person Italian Analysis - Mark Mascolini (11/08/17)   Treated people living with HIV show poorer cognitive performance at baseline but similar longitudinal changes over two years compared to appropriately chosen controls - (11/08/17)   Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial (ASPIRE) - (11/08/17)   Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts - (11/08/17)   HIGH PREVALENCE AND BURDEN OF PAIN IN PEOPLE LIVING WITH HIV: THE POPPY STUDY - (11/08/17)   Associations Between Subcutaneous Fat Density and Metabolic and Inflammatory Biomarkers Differ by HIV Serostatus and Are Independent of Fat Quantity - (11/08/17)   "Use of integrase inhibitors is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters: an ATHENA cohort study" - Mark Mascolini (11/06/17)   Bigger Weight Gains With Contemporary PI Regimens Than With NNRTIs or INIs - Mark Mascolini (11/06/17)   Predictors of Stopping Dolutegravir or Elvitegravir in Large Netherlands Group - ATHENA Cohort - Mark Mascolini (11/06/17)   Impacts of HIV Duration (Under 10 vs Over 20 Years) in People 50 or Older - Mark Mascolini (11/06/17)   "Switching boosters: are they equal? An analysis of patients switching from ritonavir to cobicistat in a large London cohort" - Mark Mascolini (11/06/17)   Successful Attempt to Counter Hep A Outbreak in Paris MSM With HAV Vaccine - Mark Mascolini (11/06/17)   In Over-60 Group, Longer Known HIV Duration Tied to Kidney Disease - Mark Mascolini (11/06/17)   More HIV/STI Testing, Fewer Risk Habits With Chemsex Program for London MSM - Mark Mascolini (11/06/17)   Clinical outcomes among persons living with HIV (PLWH) initiating dolutegravir-based vs. other recommended regimens in clinical care from the Centers for AIDS Research Network of Integrated Systems (CNICS) - Mark Mascolini (11/06/17)   Twice-Daily TAF May Be Option With Rifampin for TB and HIV - Mark Mascolini (11/06/17)   Phase 3 randomized controlled trial of switching to emtricitabine/tenofovir alafenamide (F/TAF) from abacavir/lamivudine (ABC/3TC) in virologically suppressed adults: week 48 results - Mark Mascolini (11/06/17)   Switching from boosted protease inhibitors (PI/r) to dolutegravir (DTG) in virologically suppressed HIV-infected patients with high cardiovascular risk: 48-week effects on subclinical cardiovascular disease (CVD) - Mark Mascolini (11/06/17)   The Burden of HCV-Related Cirrhosis Among HIV/HCV Coinfected Individuals in Spain in the DAA Era: What will the battlefield look like once the battle is over? - (11/02/17)   HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - Mark Mascolini (11/02/17)   Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - Mark Mascolini (11/02/17)   EU Patient Experience and Views on Antiretroviral Treatment: Findings From the Positive Perspectives Study - (11/02/17)   UNDERSTANDING PLWH AWARENESS AND WORRIES CONCERNING COMORBIDITIES AND OPTIMIZATION THERAPY: RESULTS FROM AN ITALIAN WEB SURVEY - (11/02/17)   Tolerability and persistence of dolutegravir-based regimens: Second interim analysis of the prospective multicenter DOL-ART cohort - (11/02/17)   Socio-structural Factors Surrounding Long Acting Injectable ART: A Qualitative Study Among PLHIV Participating in a Phase II Study of Cabotegravir + Rilpivirine (LATTE-2) in the US and Spain - (11/02/17)   Abacavir Hypersensitivity Reaction Reporting Rates in a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure - (11/02/17)   Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort - (11/02/17)   Rate of Progression to Osteoporosis in a Large Cohort of HIV-Infected Subjects. - (11/02/17)   Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase inhibitors Results from the EuroSIDA study. - (11/02/17)   Effectiveness and tolerability of Triumeq(DTG/ABC/3TC) in routine clinical care in Germany: First interim analysis of the TRIUMPH cohort - (11/02/17)   Predictors of Changes in Bone Mineral Density and Proteinuria From 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - full poster report - (11/02/17)   Predictors of Changes in Bone Mineral Density and Proteinuria from 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - (11/02/17)   Twice Daily Administration of Tenofovir Alafenamide in Combination with Rifampin: Potential for Tenofovir Alafenamide Use in HIV-TB Coinfection - (11/02/17)   Planned 24-week analysis of two dolutegravir (DTG)-based simplification strategies - (11/02/17)   Relationships between bone density, bone quality and reported fractures within the HIV UPBEAT cohort - (10/31/17)   The contribution of HIV to reduced bone mineral density (BMD): the POPPY Study - (10/31/17)   Plasma and Seminal Pharmacokinetics of Etravirine and Raltegravir in a Dual Regimen maintenance strategy: ANRS-163 ETRAL - (10/31/17)   Efficacy of dolutegravir-based regimens in suppressing HIV-RNA in paired blood and semen samples in ART-naïve HIV-1 infected men - (10/31/17)   Dolutegravir-based Simplified Maintenance Therapy in HIV-infected Patients a Systematic Review and Meta-analysis - (10/31/17)   Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted protease inhibitor plus lamivudine for maintenance of virological suppression Gesida study 9717 - (10/31/17)   Subgroup Analyses From ONCEMRK: a Phase 3 Study of Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily in HIV-1-Infected Treatment-Naïve Adults at Week 96 - (10/31/17)   Subgroup Analyses From DRIVE-FORWARD, a Phase 3 Trial of Doravirine Versus Ritonavir-Boosted Darunavir in Treatment-Naïve HIV-1-Infected Participants at Week 48 - (10/31/17)   Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) versus darunavir/cobicistatplus emtricitabine/tenofovirdisoproxilfumarate - (10/30/17)   ABX464 Decreases Total HIV DNA and Integrated HIV DNA in PBMCs When Administered During 28 Days to HIV-infected Virologically Suppressed Patients - (10/30/17)   Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: Day 8 and Week 24 Primary Efficacy and Safety Results (BRIGHTE Study, Formerly 205888/AI438-047) - (10/30/17)   Bone and renal safety week 48 subgroup analysis of EMERALD: A Phase 3, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults - 2/slides - (10/30/17)   Bone and renal safety Week 48 subgroup analysis of EMERALD:A Phase III, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults - (10/30/17)   Relative Bioavailability of Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Single-Tablet Regimen When Administered as a Whole, Split, or Crushed Tablet - (10/30/17)   Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate - (10/30/17)   High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)   Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - written by Mark Mascolini (10/30/17)   HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - written by Mark Mascolini (10/30/17)   Impact of Diabetes and Age on Kidneys During DAA Therapy for HCV/HIV - written by Mark Mascolini (10/30/17)   Global Analysis Projects World Far From Goal of Eliminating HCV - written by Mark Mascolini (10/30/17)   High SVR 12 rates with grazoprevir/elbasvir ± ribavirin for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM in the Swiss HCVree Trial (10/30/17)   Cure Rate 99% With Grazoprevir/Elbasvir in HCV/HIV-Infected MSM in Switzerland - written by Mark Mascolini (10/29/17)   Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)   Women 65 or Older Have Worse Virologic Control Than Men in Italian Cohort - written by Mark Mascolini (10/29/17)   Atorvastatin Slows Kidney Function Drop More Than Nonstatin Antilipid Agents - written by Mark Mascolini (10/29/17)   Current Pain Risk Higher in Older HIV+ Group vs Older HIV- and Younger HIV+ - written by Mark Mascolini (10/29/17)   Nonavalent HPV Vaccine May Have Protected 77% of HIV+ Men With Anal HPV - written by Mark Mascolini (10/29/17)   Raltegravir/Etravirine Effective Maintenance Through 48 Weeks in 45 or Older Group - written by Mark Mascolini (10/29/17)   HIV Resistance Prevalence Flat in Italy Over Past 5 Years - written by Mark Mascolini (10/29/17)   AIDS, Liver Disease Down as Death Causes in Paris HIV Group; Cancer and CVD Up - written by Mark Mascolini (10/29/17)   Meta-analysis Finds Little Evidence of Worse Side Effect Rates With Dolutegravir - written by Mark Mascolini (10/29/17)   First-Line Responses Similar With Integrase Inhibitors and NNRTIs in UK - written by Mark Mascolini (10/29/17)   Resistance at Failure Less Likely With Dolutegravir Than Raltegravir or Elvitegravir - written by Mark Mascolini (10/29/17)   Antiretrovirals Pose Highest Cost in Large Swiss HIV Care Analysis - written by Mark Mascolini (10/29/17)   Bone Density Lower With Than Without HIV in People 50 or Older - written by Mark Mascolini (10/29/17)   Novel Antiretroviral Cuts HIV DNA in PBMCs When Added to Solo Darunavir - written by Mark Mascolini (10/29/17)   Meta-Analysis Sees Good Results With Dolutegravir-Based Dual Maintenance - written by Mark Mascolini (10/29/17)   Switch to Boosted PI/3TC Noninferior to Triple Therapy in 4-Trial Analysis - written by Mark Mascolini (10/29/17)   Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)   ViiV at EACS 2017 - Tackling HIV Challenges in Europe - (10/28/17)   New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV - self-stigma, treatment, attitudes - (10/26/17)   Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial - (10/26/17)